CJC-1295 is a growth hormone releasing peptide that works similarly to tesamorelin: it binds to GHRH receptors and signals the pituitary to produce GH
The 72-hour minimum gap between any two injections prevents plasma drug levels from stacking to supratherapeutic concentrations, which increases the risk of GI adverse events (nausea, vomiting, diarrhea) that are already the most common reason patients discontinue GLP-1 therapy
This degradation compromises the molecular integrity of the active ingredient, potentially resulting in diminished glycaemic control
Vitamin B12 works with folate and produces a compound S-adenosylmethionine that creates and regulates hormones, helps regulate moods and the immune system
Across the placebo- and active-controlled glycemic control trials, 32 out of 3,150 (1%) OZEMPIC-treated patients developed ADAs to the active ingredient in OZEMPIC (i.e., semaglutide)